SCHEMBL3633446

SCHEMBL3633446

O=C(O)N1CCC(O)(c2ccc(Br)cc2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CCR1 P32246 2/20 0.49
OPRM1 P35372 3/20 0.49
OPRK1 P41145 3/20 0.49
OPRD1 P41143 2/20 0.49
OPRL1 P41146 2/20 0.49
ACE2 Q9BYF1 1/20 0.48
S1PR2 O95136 1/20 0.44
DRD2 P14416 4/20 0.42
DRD3 P35462 4/20 0.42
NR1I2 O75469 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427539 0.90 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL15156081 0.86 OPRM1 (0.43) CA12CA1CA2CA7CA9
SCHEMBL23706089 0.85 ALDH1A1 (0.50) CA12CA1CA2CA7CA9
SCHEMBL3541960 0.84 DRD2 (0.49) CCR1OPRM1OPRK1OPRD1OPRL1
SCHEMBL4622767 0.84 KMT2A (0.56) CA12CA1CA2CA7CA9
SCHEMBL14748330 0.80 OPRL1 (0.48) CCR1OPRM1OPRK1OPRD1OPRL1
SCHEMBL16936646 0.79 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL578234 0.79 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL3695939 0.79 RORC (0.54) CA12CA1CA2CA7CA9
SCHEMBL17654337 0.78 ALDH1A1 (0.38) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed
EP-2142521-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME Abbott Laboratories (US) 2010-01-13 EP disclosed
WO-2008134693-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA CA12 969/4885CA1 1590/4885CA2 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.